LEVETIRACETAM DEXCEL 500

Nazione: Israele

Lingua: inglese

Fonte: Ministry of Health

Principio attivo:

LEVETIRACETAM

Commercializzato da:

DEXCEL PHARMA TECHNOLOGIES LTD

Codice ATC:

N03AX14

Forma farmaceutica:

TABLETS

Composizione:

LEVETIRACETAM 500 MG

Via di somministrazione:

PER OS

Tipo di ricetta:

Required

Prodotto da:

DEXCEL LTD, ISRAEL

Gruppo terapeutico:

LEVETIRACETAM

Area terapeutica:

LEVETIRACETAM

Indicazioni terapeutiche:

Levetiracetam Dexcel is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Dexcel is indicated as adjunctive therapy:• In the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy.• In the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.• In the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.

Data dell'autorizzazione:

2018-03-31